I'm willing to give Gerald the benefit of the doubt and assume that he has a "big picture" scenario in which delaying the disclosure of the LymPro data at the A.A.I.C. was the correct decision.

I expect that by the end of July that it will be obvious to the shareholders and the market why he chose the current course of action.

Interesting days and weeks ahead.

Twitter: @AmarantusBio .... 10,000+ followers.